IC
AVDL

Ikarian Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Ikarian Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-54,694
Closed -$366K – 302
2020
Q4 		$366K Hold
54,694
– – 0.02% 200
2020
Q3 		$275K Sell
54,694
-432,449
-89% -$3.15M 0.02% 151
2020
Q2 		$3.94M Buy
487,143
+405,000
+493% +$3.57M 0.31% 75
2020
Q1 		$652K Buy
+82,143
New +$631K 0.05% 127

Other funds holding AVDL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Ikarian Capital's AVDL Position: Q1 2021 in Review

Ikarian Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 54,694 shares — an estimated $366K sold.

Ikarian Capital first reported a position in AVDL in Q1 2020 and held it in 4 quarters. The position peaked at $3.94M in Q2 2020. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

  • Ikarian Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Ikarian Capital sold 54,694 Avadel Pharmaceuticals shares in Q1 2021, an estimated $366K.
  • Ikarian Capital first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Ikarian Capital's Avadel Pharmaceuticals position peaked at $3.94M in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.